Mirum Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Mirum Pharmaceuticals does not have a record of paying a dividend.

Wichtige Informationen

n/a

Dividendenausschüttung

-11.3%

Rückkaufsrendite

Gesamte Aktionärsrendite-11.3%
Zukünftige Dividendenrendite0%
Wachstum der Dividenden/a
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Ausschüttungsquoten/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Nov 03
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Oct 04

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 17

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Jul 13
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

May 28
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26
There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if MIRM's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if MIRM's dividend payments have been increasing.


Dividendenrendite im Vergleich zum Markt

Mirum Pharmaceuticals Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von MIRM im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (MIRM)n/a
Untere 25 % des Marktes (US)1.5%
Markt Top 25 % (US)4.5%
Branchendurchschnitt (Biotechs)2.2%
Analystenprognose (MIRM) (bis zu 3 Jahre)0%

Bemerkenswerte Dividende: Unable to evaluate MIRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate MIRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate MIRM's payout ratio to determine if its dividend payments are covered by earnings.


Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as MIRM has not reported any payouts.


Entdecken Sie dividendenstarke Unternehmen